Sibrotuzumab is the humanized antibody targeting FAP By using [131I]sibrotuzumab, researchers found that the antibody mainly uptakes in the tumour sites instead of normal tissue sites.110 Therefore, the advantage of targeting FAP is sibrotuzumab could successfully uptake in tumour sites because of FAP is not widely expressed in normal tissues antigen pool. The gene discussed is FAP; the disease is neoplasm.